Cargando…

Efficacy and Safety of Cladribine: Subcutaneous versus Intravenous Administration in Hairy Cell Leukemia Patients

Cladribine induces durable complete remission (CR) in approximately 85% of hairy cell leukemia (HCL) patients. In Egypt, cladribine is mainly used as IV continuous infusion at a dose of 0.1 mg/kg/day for 7 days and as SC bolus injection at a dose of 0.14 mg/kg/day for 5 days. We aimed to compare the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Khorshid, Ola, Namour, Alfred Elias, El-Gammal, Mosaad M, Mahmoud, Tarek Yakout, Fortpied, Catherine, Abdel-Malek, Raafat, Ramadan, Safaa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Università Cattolica del Sacro Cuore 2015
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4621169/ https://www.ncbi.nlm.nih.gov/pubmed/26543527 http://dx.doi.org/10.4084/MJHID.2015.058

Ejemplares similares

Remarkable Response of Hairy Cell Leukemia Variant to Single-Agent Cladribine
por: Otieno, Steve B, et al.
Publicado: (2022)

Treatment of Classic Hairy Cell Leukemia: Targeting Minimal Residual Disease beyond Cladribine
por: Bohn, Jan-Paul, et al.
Publicado: (2022)

Complete recovery of pyoderma gangrenosum after successful treatment of underlying hairy cell leukemia with cladribine
por: Tombak, Anıl, et al.
Publicado: (2015)

Severe Systemic Rash in the Treatment of Hairy Cell Leukemia with Cladribine: Case Report and Literature Review
por: Dong, Huijie, et al.
Publicado: (2020)

Subcutaneous cladribine to treat multiple sclerosis: experience in 208 patients
por: Allen-Philbey, Kimberley, et al.
Publicado: (2021)

Outcome of hairy cell leukemia patients treated with cladribine – a 10-year single-center experience in Pakistan
por: Zahid, Mohammad Faizan, et al.
Publicado: (2019)

A 3-decade multicenter European experience with cladribine as upfront treatment in 384 patients with hairy cell leukemia
por: Broccoli, Alessandro, et al.
Publicado: (2022)

Severe lymphopenia after subcutaneous cladribine in a patient with multiple sclerosis: To vaccinate or not?
por: Mateo-Casas, M., et al.
Publicado: (2020)

Long term follow-up of a phase II study of cladribine with concurrent rituximab with hairy cell leukemia variant
por: Chihara, Dai, et al.
Publicado: (2021)

Long-term follow-up of cladribine treatment in hairy cell leukemia: 30-year experience in a multicentric Italian study
por: Pagano, Livio, et al.
Publicado: (2022)

Hairy Cell Leukemia Presenting with Isolated Skeletal Involvement Successfully Treated by Radiation Therapy and Cladribine: A Case Report and Review of the Literature
por: Yonal-Hindilerden, Ipek, et al.
Publicado: (2015)

Efficacy and Safety of Intravenous Cladribine in Patients with Rapidly Evolving or Early Secondary Progressive Multiple Sclerosis
por: Alshamrani, Foziah, et al.
Publicado: (2020)

Application of population pharmacokinetics to cladribine
por: Lindemalm, Synnöve, et al.
Publicado: (2005)

Cladribine: Lymphopenia: case report
Publicado: (2021)

Payer Perspectives on Intravenous versus Subcutaneous Administration of Drugs
por: Epstein, Robert S
Publicado: (2021)

Cladribine modifies functional properties of microglia
por: Jørgensen, L. Ø., et al.
Publicado: (2020)

Cladribine: Lymphopenia: 2 case reports
Publicado: (2020)

Immunomodulatory Effects Associated with Cladribine Treatment
por: Fissolo, Nicolás, et al.
Publicado: (2021)

On the Subcutaneous Injection of Blood, Infusion (Subcutaneous) and Intravenous Transfusion
por: Oehler,, et al.
Publicado: (1888)

Pharmacokinetics of Tildipirosin in Ewes after Intravenous, Intramuscular and Subcutaneous Administration
por: Galecio, Juan Sebastián, et al.
Publicado: (2020)

Robenacoxib pharmacokinetics in sheep following oral, subcutaneous, and intravenous administration
por: Fadel, Charbel, et al.
Publicado: (2022)

Long-Term Safety and Efficacy of Subcutaneous Cladribine Used in Increased Dosage in Patients with Relapsing Multiple Sclerosis: 20-Year Observational Study
por: Rejdak, Konrad, et al.
Publicado: (2021)

Erdheim Chester Disease treated successfully with cladribine
por: Azadeh, Natalya, et al.
Publicado: (2016)

Population Pharmacokinetics of Cladribine in Patients with Multiple Sclerosis
por: Savic, Radojka M., et al.
Publicado: (2017)

Cladribine Tablets: A Review in Relapsing MS
por: Deeks, Emma D.
Publicado: (2018)

Expert-Agreed Practical Recommendations on the Use of Cladribine
por: Meca-Lallana, Virginia, et al.
Publicado: (2022)

Magnetic Multi-Enzymatic System for Cladribine Manufacturing
por: Cruz, Guillermo, et al.
Publicado: (2022)

Disposition Kinetic of Moxifloxacin following Intravenous, Intramuscular, and Subcutaneous Administration in Goats
por: Patel, Harshad B., et al.
Publicado: (2011)

Pharmacokinetics of placental protein 13 after intravenous and subcutaneous administration in rabbits
por: Drobnjak, Tijana, et al.
Publicado: (2018)

Comparative Cost Analysis Of Intravenous And Subcutaneous Administration Of Rituximab In Lymphoma Patients
por: Delgado Sánchez, Olga, et al.
Publicado: (2019)

Pharmacokinetics and Immunogenicity of Frunevetmab in Osteoarthritic Cats Following Intravenous and Subcutaneous Administration
por: Walters, Rodney R., et al.
Publicado: (2021)

Chronic Cladribine Administration Increases Amyloid Beta Peptide Generation and Plaque Burden in Mice
por: Hayes, Crystal D., et al.
Publicado: (2012)

The optimal choice of medication administration route regarding intravenous, intramuscular, and subcutaneous injection
por: Jin, Jing-fen, et al.
Publicado: (2015)

Population Modelling of Dexmedetomidine Pharmacokinetics and Haemodynamic Effects After Intravenous and Subcutaneous Administration
por: Ashraf, Muhammad W., et al.
Publicado: (2020)

Serum concentration and safety of intravenous drip versus subcutaneous administration of carboplatin in dogs
por: IWANO, Masataka, et al.
Publicado: (2021)

Pharmacokinetics of glucagon after intravenous, intraperitoneal and subcutaneous administration in a pig model
por: Teigen, Ingrid Anna, et al.
Publicado: (2022)

Pharmacokinetics of esomeprazole in goats (Capra aegagrus hircus) after intravenous and subcutaneous administration
por: Fladung, Rachel, et al.
Publicado: (2022)

A Comparison of Subcutaneous with Intravenous and Intrathecal Administration of Tetanus Antitoxin in Experimental Tetanus
Publicado: (1918)

Correction to: Cladribine Tablets: A Review in Relapsing MS
por: Deeks, Emma D.
Publicado: (2019)

Expert opinion on the use of cladribine tablets in clinical practice
por: Sørensen, Per Soelberg, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_hljd5u6pnii05vin82g8q0jmfr